» Articles » PMID: 31703564

Human Cytomegalovirus Seroprevalence and Titres in Solid Organ Transplant Recipients and Transplant Donors in Seoul, South Korea

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2019 Nov 10
PMID 31703564
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human cytomegalovirus (HCMV) can cause poor outcomes in solid organ transplant (SOT) recipients; moreover, it is associated with cardiovascular diseases (CVD) in the general population. Accordingly, anti-HCMV immunoglobulin G (IgG) seroepidemiology may be useful in identifying the risk of post-SOT HCMV infection or disease as well as immunosenescence or CVD. However, HCMV seroprevalence and titre have not been fully evaluated with regard to age distribution or compared between SOT recipients and healthy individuals in South Korea.

Methods: We retrospectively retrieved all unduplicated anti-HCMV IgG results of individuals aged > 1 year evaluated between July 2006 and November 2017 at Severance Hospital in Seoul. The cohort, excluding haematopoietic stem cell transplant recipients and subjects with equivocal values, included 2184 SOT recipients and 3015 healthy transplant donors. All IgG results in the SOT recipients were measured during the pre-transplant period.

Results: The overall IgG seroprevalence and titres were significantly higher among SOT recipients than among healthy donors (98.7% vs. 88.6%, p < 0.001, and 64.7 ± 44.3 vs. 49.8 ± 20.6 arbitrary units/mL, p < 0.001, respectively). The lowest seropositive rate in the SOT group was observed in recipients aged between 11 and 15 years (70.6%). The frequency of seropositivity among adults aged ≥41 years increased to ≥90% in SOT recipients and healthy donors. Age was independently associated with higher HCMV seroprevalence (41-60 years, OR, 76.4, 95% CI, 24.5-238.9, p < 0.001; ≥ 61 years, OR, 4.4, 95% CI, 1.3-14.9, p < 0.001, compared to ≤40 years). The healthy donor group had an independently low HCMV seropositive rate (OR, 0.1, 95% CI, 0.1-0.2, p < 0.001).

Conclusions: HCMV seropositivity was the lowest among school-aged children and adolescents. IgG testing revealed an intermediate serostatus risk of post-transplant HCMV infection and disease for most adult SOT recipients in South Korea.

Citing Articles

Area-Level Social Deprivation and Cytomegalovirus Seropositivity at the Time of Solid Organ Transplant.

Abidi M, Lopez R, Arrigain S, Weinberg A, Kaplan B, McAdams-DeMarco M JAMA Netw Open. 2024; 7(10):e2437878.

PMID: 39374014 PMC: 11581662. DOI: 10.1001/jamanetworkopen.2024.37878.


Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation.

Huh K, Lee S, Kim J, Lee S, Choe P, Kang J Infect Chemother. 2024; 56(1):101-121.

PMID: 38527780 PMC: 10990892. DOI: 10.3947/ic.2024.0016.


Cytomegalovirus reactivation under pre-emptive therapy following allogeneic hematopoietic stem cell transplant: Pattern, survival, and risk factors in the Republic of Korea.

Kang K, Jeon M, Yu E, Kim D, Lee B, Lee S PLoS One. 2023; 18(9):e0291268.

PMID: 37703263 PMC: 10499250. DOI: 10.1371/journal.pone.0291268.


Challenges, Recent Advances and Perspectives in the Treatment of Human Cytomegalovirus Infections.

Chen S, Wang S, Chen Y Trop Med Infect Dis. 2022; 7(12).

PMID: 36548694 PMC: 9784992. DOI: 10.3390/tropicalmed7120439.


Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study.

Ju C, Wang X, Xu X, Xie S, Cao Q, Lin W BMC Infect Dis. 2022; 22(1):872.

PMID: 36418967 PMC: 9682642. DOI: 10.1186/s12879-022-07853-x.


References
1.
Kaminski H, Fishman J . The Cell Biology of Cytomegalovirus: Implications for Transplantation. Am J Transplant. 2016; 16(8):2254-69. DOI: 10.1111/ajt.13791. View

2.
Hamprecht K, Bissinger A, Arellano-Galindo J, Schweinzer K, Jiang X, Gohring K . Intrafamilial transmission of human cytomegalovirus (HCMV): long-term dynamics of epitope-specific antibody response in context of avidity maturation. J Clin Virol. 2014; 60(2):119-26. DOI: 10.1016/j.jcv.2014.03.006. View

3.
Weltevrede M, Eilers R, de Melker H, van Baarle D . Cytomegalovirus persistence and T-cell immunosenescence in people aged fifty and older: A systematic review. Exp Gerontol. 2016; 77:87-95. DOI: 10.1016/j.exger.2016.02.005. View

4.
Seale H, MacIntyre C, Gidding H, Backhouse J, Dwyer D, Gilbert L . National serosurvey of cytomegalovirus in Australia. Clin Vaccine Immunol. 2006; 13(11):1181-4. PMC: 1656547. DOI: 10.1128/CVI.00203-06. View

5.
Kim J, Kim A, Shin E . Cytomegalovirus Infection and Memory T Cell Inflation. Immune Netw. 2015; 15(4):186-90. PMC: 4553256. DOI: 10.4110/in.2015.15.4.186. View